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Allogeneic stem cell transplantation (allo-SCT) can induce remission in patients with hematologic malig-
nancies due to graft-versus-tumor (GVT) responses. This immune-mediated antitumor effect is often
accompanied by detrimental graft-versus-host disease (GVHD), however. Both GVT and GVHD are mediated
by minor histocompatibility antigen (MiHA)-speciﬁc T cells recognizing peptide products from polymorphic
genes that differ between recipient and donor. In this study, we evaluated whether mismatches in a panel of
17 MiHAs are associated with clinical outcome after partially T celledepleted allo-SCT. Comprehensive
statistical analysis revealed that DNA mismatches for one or more autosomal-encoded MiHAs was associated
with increased relapse-free survival in recipients of sibling transplants (P ¼ .04), particularly in those with
multiple myeloma (P ¼ .02). Moreover, mismatches for the ubiquitous Y chromosomeederived MiHAs
resulted in a higher incidence of acute GVHD grade III-IV (P ¼ .004), whereas autosomal MiHA mismatches,
ubiquitous or restricted to hematopoietic cells, were not associated with severe GVHD. Finally, we found
considerable differences among MiHAs in their capability of inducing in vivo T cell responses using dual-color
tetramer analysis of peripheral blood samples collected after allo-SCT. Importantly, detection of MiHA-speciﬁc
T cell responses was associated with improved relapse-free survival in recipients of sibling transplants
(P ¼ .01). Our ﬁndings provide a rationale for further boosting GVT immunity toward autosomal MiHAs with
a hematopoietic restriction to improve outcomes after HLA-matched allo-SCT.
 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.INTRODUCTION
Allogeneic stem cell transplantation (allo-SCT) combined
with donor lymphocyte infusion (DLI) is a potent treatment
for patients with hematologic malignancies [1,2]. Numerous
clinical and experimental studies in HLA-identical allo-SCT
provide evidence that both the potentially curative graft-
versus-tumor (GVT) effect and graft-versus-host disease
(GVHD) develop as a result of donor T cell responses directed
against disparate minor histocompatibility antigens (MiHAs)
[3-5]. These MiHAs are polymorphic HLA-bound peptides
derived from cellular proteins that can induce powerful
alloreactive T cell responses. It has been demonstrated
that emergence of MiHA-speciﬁc T cells precedes clinicaledgments on page 281.
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12.09.008remission in patients treated with DLI [4,6,7]. Although
various MiHAs, including Y chromosomeeencoded MiHAs,
are expressed ubiquitously, increasing numbers of autosomal-
encoded MiHAs expressed exclusively by hematopoietic cells
and their malignant counterparts are being identiﬁed [8-10].
The molecular identiﬁcation of these GVHD- and GVT-
associated MiHAs has made it possible to study the clinical
impact ofMiHAmismatches and their speciﬁc Tcell responses
after allo-SCT.
Several studies of HLA-matched allo-SCT have reported an
association betweenMiHAmismatches and clinical outcome.
Mismatches in individual MiHAs, including HA1, HA2, and
HA8, have been associated with increased rates of GVHD and
lower rates of relapse in some studies [11-13], although other
studies did not conﬁrm these results [14-16]. Furthermore,
previous studies have mainly investigated cohorts of HLA-
matched noneT celledepleted transplants and found an
increased rate of chronic GVHD (cGVHD) and a reduced
relapse rate only with HY MiHA disparity [17,18]. Moreover,
investigations of the role of MiHA incompatibility in trans-
plantation outcome have been hampered by the requirementTransplantation. Published by Elsevier Inc. All rights reserved.
Table 1
Recipient, Donor, and SCT Characteristics (n ¼ 327)
Characteristic Value
Recipient age, years, mean (range) 46 (18-67)
Donor age, years, mean (range) 46 (11-71)
Recipient male sex, n (%) 195 (60)
Donor male sex, n (%) 191 (58)
Donorerecipient sex match, n (%)
Male patientefemale donor 76 (23)
Other 251 (77)
Donor relation, n (%)
Matched sibling donor 264 (81)
Matched unrelated donor 63 (19)
Disease category, n (%)
Acute myelogenous leukemia/myelodysplastic
syndrome
118 (36)
Acute lymphoblastic leukemia 34 (10)
Chronic myelogenous leukemia 53 (16)
Non-Hodgkin lymphoma/chronic lymphocytic
leukemia
67 (20)
MM 55 (17)
Stem cell source
Mobilized peripheral blood, n (%) 175 (54)
CD34 106/kg, median (range) 5.6 (1.3-13.8)
CD3 106/kg, median (range) 0.5 (0.04-1.7)
Bone marrow, n (%) 152 (46)
CD34 106/kg, median (range) 1.9 (0.5-6.5)
CD3 106/kg, median (range) 0.7 (0.5-1.1)
Date of SCT, n (%)
1995-1999 98 (30)
2000-2004 83 (25)
2005-2010 146 (45)
Conditioning regimens, n (%)
Myeloablative
(Idarubicin)-cyclophosphamide-busulfan 18 (5.5)
(Idarubicin)-cyclophosphamide-TBI 182 (55.5)
Cyclophosphamide-ATG-busulfan 8 (2.5)
Cyclophosphmycophenolate
mofetilamide-ATG-TBI
39 (12)
Nonmyeloablative
Fludarabine-cyclophosphamide 50 (15.5)
Fludarabine-cyclophosphamide-ATG 16 (5)
TBI alone 14 (4)
GVHD prophylaxis, n (%)
Cyclosporine alone 305 (93)
Cyclosporine/mycophenolate mofetil 13 (4)
None 9 (3)
Disease status, n (%)
Early 193 (59)
Intermediate 81 (25)
Advanced 53 (16)
Interval between diagnosis and SCT, n (%)
1 year 205 (62.5)
>1 year 122 (37.5)
Cytomegalovirus status, n (%)
Negative/negative 76 (23)
Other combination 229 (70)
Missing 22 (7)
Gratwohl score, n (%)
0 30 (9)
1 183 (56)
2 93 (28.5)
3 21 (6.5)
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frequencies of particular MiHA alleles. Recently, however, it
was reported that patients with HLA-A2þ chronic myeloge-
nous leukemiawho developed acute GVHD (aGVHD) showed
improved overall survival (OS) and relapse-free survival
(RFS) when receiving a transplant from an HA1-mismatched
donor [19].
In this study, we performed a retrospective analysis on the
impact of a panel of 17 immunogenic MiHA mismatches in
a relatively large cohort of patients who underwent partially
T celledepleted allo-SCT. In recipients of sibling transplants,
mismatches in one or more of the studied autosomal-
encoded MiHAs resulted in improved RFS (P ¼ .04), espe-
cially in patients with multiple myeloma (MM) (P ¼ .02). In
contrast, no signiﬁcant association between autosomal MiHA
mismatches and aGVHD or cGVHDwas observed, whereas an
HY disparity was associated with an increased rate of grade
III-IV aGVHD (P ¼ .004). Finally, here we describe for the ﬁrst
time the potential of disparate MiHAs to induce productive T
cell responses posttransplantation. Tetramer analysis
revealed that a strong variation in the ability of different
MiHAs to mount speciﬁc CD8þ T cell responses post-
transplantation (0%-60%). More important, the presence of
MiHA-speciﬁc Tcell immunity was associatedwith improved
RFS, without inducing severe aGVHD or cGVHD. Taken
together, these data provide a rationale for further boosting
GVT immunity toward autosomal hematopoietic-restricted
MiHAs to improve RFS in recipients of HLA-matched allo-SCT.
PATIENTS AND METHODS
Patients and Donors
This study included a total of 327 adult allo-SCT recipients and their
donors. They were selected from the total transplantation cohort of our
center, who underwent HLA-matched, partially T celledepleted allo-SCT for
a hematologic malignancy between 1995 and 2010. HLA was typed using
sequence-speciﬁc PCR. Recipients of sibling transplants underwent trans-
plantation with an HLA-identical sibling donor graft, and recipients of
matched unrelated donor (MUD) grafts underwent transplantation with an
8-10 of 10 HLA-matched voluntary donor, not considering HLA-DP. Only
donorerecipient couples with HLA types HLA-A1, -A2, -A3, -A24, -B7, -B8, or
-B44 were included, because the selected set of MiHAs was restricted to
these HLA types. Furthermore, couples were selected based on the avail-
ability of both patient and donor material. Table 1 reports characteristics of
patients, donors, and allo-SCT procedures. All patients and donors had
provided informed consent for the prospective collection of data and
samples for investigational use. The study was approved by the Radboud
University Nijmegen Medical Centre’s Institutional Review Board.
Treatment Protocol
All patients were treated in accordance with previously reported
protocols [20-22]. Myeloablative conditioning regimens consisted of cyclo-
phosphamide 60 mg/kg for 2 days in combination with either total body
irradiation (TBI; 4.5 Gy for 2 days) or busulfan (4 mg/kg for 4 days). Idar-
ubicin (42 mg/m2 over 48 hours i.v.) was often added to reduce the risk of
relapse in the setting of partially Tcelledepleted SCT [23]. Nonmyeloablative
conditioning regimens consisted mainly of cyclophosphamide (1200 mg/m2
for 4 days) in combination with ﬂudarabine (30 mg/m2 for 4 days), and
sometimes only TBI (2 Gy). Patients receiving a MUD graft received antith-
ymocyte globulin (ATG) (2 mg/kg for 4 days). After conditioning, patients
received a partially T celledepleted graft derived either from bone marrow
(BM) or mobilized peripheral blood stem cells (PBSCs). The median number
of CD34þ stem cells in the graft was 1.9  106 cells/kg (range, 0.5-6.5  106
cells/kg) for BM and 5.6  106 cells/kg (range, 1.3-13.8  106 cells/kg) for
PBSCs, and the median number of CD3þ T cells was 0.7 106 Tcells/kg in BM
grafts and 0.5  106 T cells in PBSC grafts (Table 1). GVHD prophylaxis
consisted of cyclosporine A (CsA) only in themajority of patients, at a dosage
of 1.5 mg/kg i.v. twice daily for the ﬁrst 2 weeks and 1 mg/kg i.v. twice daily
or 2.5-3 mg/kg orally twice daily thereafter. CsA was tapered in the absence
of GVHD starting at 2 months posttransplantation and stopped at 3 months.
Several patients received prophylactic or therapeutic DLI after allo-SCT.
Prophylactic DLI was restricted to patients who had been off CsA therapy
for at least 3 months and had not developed aGVHD grade II-IV or cGVHD.Deﬁnition of Outcome Variables
Acute GVHD was graded according to the criteria of Przepiorka et al.
[24], and cGVHDwas classiﬁed according to the revised Seattle criteria of Lee
et al. [25] Patient risk scores for outcome were determined based on the
Gratwohl score [26]. OS, RFS, and nonrelapse mortality (NRM) were deﬁned
according to the standard criteria proposed by the European Group for Blood
and Marrow Transplantation.
MiHA Genotyping Using the KASPar System
HLA-matched SCT donorerecipient pairs were genotyped for a panel of
17 MiHAs with the KASPar assay system (KBioscience, Hoddesdon, UK),
a ﬂuorescence-based competitive allele-speciﬁc PCR using nonlabeled
primers. Details of thismethodare available at http://www.kbioscience.co.uk.
Table 2
MiHA Disparity Rate
MiHA HLA
Restriction
Peptide
Sequence
Reference Number* Disparate
Pairs, n (%)y
HA3 A1 VTEPGTAQY [40] 82/87 3 (3.7)
HA1 A2 VLHDDLLEA [41] 195/197 32 (16.4)
HA2 A2 YIGEVLVSV [42,43] 195/197 6 (3.1)
HA8 A2 RTLDKVLEV [44] 194/197 22 (11.3)
HY A2 FIDSYICQV [9] 197/197 42 (21.3)
ADIR A2 SVAPALALAFPA [45] 195/197 30 (15.4)
HwA11 A2 CIPPDSLLFPA [46] 195/197 6 (3.1)
SP110 A3 SLPRGTSTPK [47] 92/93 7 (7.6)
PANE1 A3 RVWDLPGVLK [48] 92/93 5 (5.4)
ACC1 A24 DYLQYVLQI [49] 54/54 6 (11.1)
ACC2 B44 KEFEDDIINW [49] 64/65 16 (25.0)
LRH1 B7 TPNQRQNVC [35] 97/98 19 (19.6)
HY B7 SPSVDKARAEL [8] 98/98 26 (26.5)
ECGF B7 RPHAIRRPLAL [50] 97/98 5 (5.2)
ZAPHIR B7 IPRDSWWVEL [51] 97/98 12 (12.4)
HY B8 LPHNMTDL [52] 67/67 14 (20.9)
HEATR B8 ISKERAEAL [53] 64/67 8 (12.5)
* Number of patient donor couples typed among the total number of
couples presenting with the correct HLA molecule.
y Number of disparate pairs and disparity rate of a particular MiHA were
determined within all typed couples presenting with the correct HLA
molecule.
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PE- and allophycocyanin (APC)-labeled MiHA tetramers were produced
as described previously [27]. Tetramer staining was performed directly on
cryopreserved peripheral blood mononuclear cells (PBMCs) after thawing
and at 7 days after ex vivo restimulationwith the appropriate MiHA peptide
[28]. For this, PBMCs were stimulated once with MiHA peptideepulsed (10
mM) Epstein-Barr virus lymphoblastoid cell lines (EBV-LCLs) on day 0. MiHA
peptides were loaded on a corresponding EBV-LCL stably transduced with
either HLA-A2, -A3, or -B7. For additional HLA types (eg, HLA-A24, HLA-B8),
matching healthy donor EBV-LCL were used. After initial ex vivo restim-
ulation, 100 IU/mL of IL-2 (Chiron, Emeryville, CA) and 10 ng/mL of IL-15
(Immunotools, Friesoythe, Germany) were added at days 2 and 5. For
tetramer staining,w1 106 cells were stained with 0.2 mg of tetramer for 15
minutes at room temperature. The stability of all tetramers was veriﬁed by
HPLC analysis in combination with an HLA-binding assay (MHC-ELISA or
MHC-bead assay) [29,30]. In addition, the functional reactivity of all tetra-
mers, except HEATR, was conﬁrmed by staining of cytotoxic T lymphocyte
clones speciﬁc for the corresponding epitope and subsequent ﬂow cytom-
etry analysis. After tetramer staining, cells were washed with PBS/0.5% BSA
(Sigma-Aldrich, St. Louis, MO) and labeled with Alexa Fluor 700econjugated
CD8 (Life Technologies, Grand Island, NY) in combination with FITC-
conjugated CD4, CD14, CD16, and CD19 (Beckman Coulter, Brea, CA) for 30
minutes at 4C. Finally, cells were washed and resuspended in PBS/0.5% BSA
containing 0.2 mM Sytox blue (Life Technologies), to allow exclusion of dead
cells. Data acquisition was performed on a Cyan-ADP analyzer (Beckman
Coulter) and analyzed with Kaluza 1.1 software (Beckman Coulter). CD8þ T
cells were deﬁned as viable Sytox blueenegative, CD8-positive, and CD4-,
CD14-, CD16-, and CD19-negative (on FITC) single-cell lymphocytes. Within
the CD8þ T cell population, cells positive for both tetramers (APC and PE)
were quantiﬁed (Supplemental Figure 1). Patients were classiﬁed as having
a positive tetramer response when MiHA-speciﬁc CD8þ T cells (0.01%
tetramer-positive cells within the CD8þ T cell population) were found either
directly after thawing and/or at 7 days after peptide ex vivo restimulation
using peripheral blood samples obtained during the effector or memory
phase of the immune response.
Statistical Analysis
The outcome variables aGVHD and cGVHD, relapse, RFS, OS, and NRM
after allo-SCT were analyzed in relation toMiHA disparity. Associations with
RFS and OS were analyzed using Kaplan-Meier curves and log-rank tests.
Statistical differences in the RFS rates at speciﬁc time points were analyzed
using Kaplan-Meier point estimates and their associated errors. Associations
with the cumulative incidence of aGVHD, cGVHD, relapse, and NRM were
estimated respecting the presence of competing risks using the Gray test
Competing risks were death within 100 days from other toxicities or relapse
for aGVHD, death after 100 days from other toxicities or relapse for cGVHD,
NRM for relapse, and death from relapse for NRM.
In cases with a P value .20 in univariate analysis, Cox regression
analysis (for the endpoints RFS and OS) and Fine-Gray regression analysis
(for the endpoints aGVHD, cGVHD, relapse, and NRM) were used to adjust
for the following confounding risk factors: patient age, stem cell source,
year of transplantation, conditioning regimen, diagnosis subgroup, cyto-
megalovirus seropositivity of either recipient and/or donor, and aGVHD
grade II-IV. Analyses were performed using SAS 8.2 software (SAS Institute,
Cary, NC) and the cmprsk package of open source language R version 2.6.2.
(www.r-project.org). P values <.05 were considered statistically signiﬁcant.
MiHA mismatch parameters were deﬁned as disparate HY (HY MiHA
restricted to HLA-A2, -B7, or -B8), disparate HA1, and disparate autosomal
MiHA (mismatched for one or more of the MiHAs listed in Table 2,
excluding HY).
RESULTS
Clinical Outcome Parameters after HLA-Matched
Allo-SCT
We analyzed clinical outcomes after partially T
celledepleted allo-SCT in 327 patients with a hematologic
malignancy. The median follow-up was 7.1 years (range, 0.5-
17 years) in patients alive at last follow-up and 1.1 years
(range, 0.05-12.6 years) in those who died. Figure 1A and B
show the survival curves for OS (5 year: 68%) and RFS (5 year:
44%) for the complete cohort. NRMafter 5 yearswas 15.6% (ie,
43.4% of all deaths; Figure 1C), and the relapse ratewas 40.4%.
Acute GVHD occurred in 19.6% of patients but was severe
(grade III-IV) in only 6.5%. Of the evaluable patients, 22.7%
developed limited cGVHD, and 14.2% had extensive cGVHD.MiHA Allele Frequency and Phenotype Disparity Rate
Recipient and donor DNA were typed to determine MiHA
allele frequency and disparity rates. Paired couples were
genotyped only when the appropriate HLA molecule to
which the MiHA is restricted was expressed, leading to
actual immunogenic disparity rates. HY.A2, HY.B7, or HY.B8
disparity was recorded when a female donor to male
recipient transplantation was performed. The highest
disparity rates within the restricting HLA type were
observed for all Y chromosomeederived MiHAs (20.9%-
26.5%), as well as for ACC2 (25.0%), LRH1 (19.6%), and HA1
(16.4%). Overall, 60 (18.2%) and 137 (41.6%) of the 327 pairs
were disparate for Y-chromosomeeencoded and autosomal
chromosomeeencoded MiHA, respectively (Table 2).
HY Disparity Associated with Increased aGVHD
The incidence of grade III-IV aGVHD at day 100 after allo-
SCTwas signiﬁcantly higher in HY-mismatched patients than
in HY-matched patients (19% versus 4%; P < .001, univariate
analysis) when respecting the presence of competing risks.
Multivariate analysis conﬁrmed this association for HY
incompatibility with the increased risk of aGVHD grade III-IV
(hazard ratio [HR], 4.1; 95% conﬁdence interval [CI], 1.6-10.3;
P < .001) (Figure 2A). Notably, none of the nonesex-linked
MiHA mismatched categories (HA1 or autosomal MiHA
mismatched) showed an association with aGVHD or cGVHD
(Figure 2A and B), possibly owing to the hematopoietic-
restricted tissue expression pattern of the majority of the
autosomal MiHAs tested.
Autosomal MiHA Disparity Is Associated with Improved
RFS in Sibling Transplants
Statistical analysis revealed that mismatches in the
studied MiHAs had no impact on RFS in the complete cohort
(Figure 3A). Because recipients of MUD grafts might have an
HLA-DPmismatch, as well as a higher rate of unknownMiHA
mismatches, we analyzed the effect of known MiHA dispar-
ities on clinical outcome separately in the sibling cohort
(n ¼ 264). Interestingly, recipients of an autosomal MiHA-
mismatched sibling graft had signiﬁcantly better RFS in
Figure 1. Clinical outcome parameters after partially T celledepleted allo-SCT in the complete cohort of allo-SCT recipients. OS (A), RFS (B), and cumulative incidence
of NRM (C) were determined by Kaplan-Meier analysis.
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(Figure 3B and Table 3). This beneﬁcial effect of autosomal
MiHA disparity on RFS could be attributed to trends toward
improved NRM (HR, 0.59; 95% CI, 0.29-1.25; P ¼ .19) and
decreased relapse (HR, 0.77; 95% CI, 0.50-1.11; P ¼ .14), as
assessed in multivariate Fine-Gray competing-risk analyses.
Furthermore, in sibling allo-SCT, HY disparity also was
associatedwith a higher incidence of grade III-IV aGVHD (HR,
4.2; 95% CI, 1.6-10.9; P ¼ .004) (Table 3).
Analysis of clinical outcomes in recipients of anMUD graft
(n ¼ 61) showed no signiﬁcant associations between MiHA
disparity and either RFS (Figure 3C) or aGVHD (data not
shown). Taken together, these data indicate that recipients of
an HLA-identical sibling donor stem cell graft mismatched
for the studied autosomal MiHA may induce beneﬁcial GVT
immunity post-SCT.Figure 2. Occurrence of GVHD after MiHA-mismatched allo-SCT. In the
complete cohort, the incidence rates of aGVHD grade III-IV (A) and limited/
extensive cGVHD (B) were determined using Fine-Gray competing-risk
regression models. Groups were categorized based on MiHA disparities in
mismatching and matching at the DNA level.Patients with MM Show Improved RFS after
Transplantation with an MiHA-Mismatched Sibling Graft
Interestingly, our multivariate analysis including correc-
tion for diagnosis subgroups revealed an association between
autosomalMiHA disparity and improved RFS in HLA-matched
sibling allo-SCT, indicating a diagnosis-independent effect. To
identify which patients would beneﬁt the most from
a disparity in the studiedMiHAs, we analyzed the inﬂuence of
MiHA mismatches on clinical outcome in different diagnosis
subgroups separately. Notably, we were able to conﬁrm
a signiﬁcant correlation between the occurrence of disparate
autosomal MiHA and clinical outcome only in the MM
subgroup. Of the 22 mismatched patients with MM, 15 were
mismatched for 1MiHA, 6weremismatched for 2MiHAs, and
1 was mismatched for 4 MiHAs. Importantly, patients with
MMwhounderwent allo-SCT had improvedRFSwhen at least
one autosomalMiHAmismatchwas present (HR, 0.41; 95% CI,
0.19-0.89; P ¼ .02) (Figure 4A). In addition, patients with an
autosomal MiHA mismatch developed signiﬁcantly less
relapse, as detected by univariate Fine-Gray competing-risk
analysis (HR, 0.46; 95% CI, 0.21-1.00; P ¼ .049) (Figure 4B).
MiHA disparity was also correlated with an increased rate of
limited cGVHD (P ¼ .03, univariate analysis) (Figure 4C).
Notably, the effects on clinical outcome parameters were not
related to differences in disease status between MiHA-
matched and MiHA-mismatched patients (Figure 4D). Inter-
estingly, 22.6% of the MiHA-mismatched patients with MM
had an HA1 disparity (Figure 4E). HA1 disparity has been re-
ported to be associated with improved RFS in patients with
chronic myelogenous leukemia who developed aGVHD [19].
Taken together, these data suggest that mismatches in the
studied MiHAs induce improved graft-versus-myeloma
immunity after partially T celledepleted sibling allo-SCT.
Ability to Induce Tetramer-Positive MiHA-Speciﬁc T Cell
Responses Varies among MiHAs
Although genetic MiHA incompatibility has a signiﬁcant
effect on clinical outcome post-SCT, this does not necessarily
mean that corresponding T cell responses actually occur.
Thus, we investigated the potential of 15 of the 17 studied
MiHAs to induce productive MiHA-speciﬁc T cell responses
in vivo. For this, we analyzed recipient PBMC material ob-
tained at the median of 9 months (range, 2-70 months) after
allo-SCT using a dual-color MiHA-multimer approach.
Patients were classiﬁed as having a positive tetramer
response when MiHA-speciﬁc CD8þ T cells were detected
directly after thawing and/or after a single ex vivo peptide
Figure 3. Autosomal MiHA disparity is associated with increased RFS after allo-SCT with a sibling graft. RFS was analyzed in the complete cohort (A) versus recipients
of a sibling graft (B) or an MUD graft (C) using the log-rank test. Groups were categorized based on autosomal MiHA disparity in mismatching (black line) and
matching (gray line) at the DNA level. Signiﬁcant P values of multivariate analyses are shown.
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patients at the same time interval, we believe that detection
of MiHA tetramerepositive CD8þ T cells at variable time
points reﬂects either an ongoing effector immune responseor
a sustained effector-memory response after immune
contraction. Figure 5A shows representative tetramer
screenings of 3 different allo-SCT recipients. In freshly thawed
samples, low numbers of MiHA-speciﬁc CD8þ T cells were
detected in 27 of 40 (67.5%) MiHA T celleresponsive patients.
In addition, in 13 of 40 (32.5%) responsive patients, tetramer-
positive T cells were detectable after 1 week of stimulation
with MiHA peptideepulsed EBV-LCL. Notably, in the whole
cohort of MiHA-mismatched recipients, certain MiHA-
speciﬁc T cell responses occurred more frequently than
others (Figure 5B). In particular, disparity for HA1, HA2,
PANE1, LRH1, ACC1, and the HY chromosomeeencoded anti-
gens HY.A2 and HY.B7 resulted in MiHA-speciﬁc CD8þ T cell
responses in 25%-60% of the MiHA-mismatched patients.
HA8-, SP110-, and ZAPHIR-speciﬁc CD8þ Tcells were found in
10%-20% of these patients. In contrast, no productive CD8þ T
cell responses against ADIR, HwA11, ECGF, HEATR, and HY.B8
were observed, despite genetic disparities. These resultsTable 3
Univariate Analysis of Patient Characteristics and Clinical Outcomes in the SIB Coh
Outcome Parameter MiHA
Disparity
Univariate Analysis Multivaria
HR (95% CI) P Value Confound
aGVHD grade III-IV HY 4.80 (2.00-11.20) <.001 Patient ag
cell sourc
MiHA 1.10 (0.50-2.50) .74 NA
cGVHD limited/extensive HY 1.30 (0.70-2.20) .44 NA
MiHA 1.01 (0.63-1.67) .96 NA
Time to relapse HY 0.58 (0.35-0.98) .04 Diagnosis
condition
MiHA 0.77 (0.53-1.11) .16 Diagnosis
condition
RFS HY 0.75 (0.49-1.16) .20 Patient ag
stem cell
MiHA 0.73 (0.52-1.03) .07 Patient ag
stem cell
OS HY 0.90 (0.52-1.55) .70 NA
MiHA 0.88 (0.56-1.35) .56 NA
NRM HY 1.30 (0.70-2.70) .43 NA
MiHA 0.59 (0.29-1.25) .13 Patient ag
seropositi
NA indicates not applicable.
Associations with OS and RFS were analyzed using Kaplan-Meier curves and log
relapse, and NRMwere estimated respecting the presence of competing risks using t
Cox regression analyses (for the endpoints OS and RFS) and Fine and Gray regression
adjust for known confounding risk factors.indicate that certain MiHAs appear to be relatively more
productive than others in inducingMiHA-speciﬁc CD8þ T cell
responses after partially T celledepleted allo-SCT.
Finally, we examined whether the presence of an MiHA-
speciﬁc T cell response, including those targeting auto-
somal MiHAs (n ¼ 25 in the complete cohort; n ¼ 20 in the
sibling graft recipients) or HY (n ¼ 15 in both the complete
cohort and the sibling graft recipients) was associated with
improved outcome posttransplantation. There were no
signiﬁcant differences in RFS curves between these groups
(complete cohort: HR, 0.82; 95% CI, 0.52-1.30; P¼ .39; sibling
graft recipients: HR, 0.73; 95% CI, 0.44-1.22; P ¼ .23).
Nevertheless, in the ﬁrst years after allo-SCT, RFS clearly
differed in patients with anMiHA-speciﬁc Tcell response and
those without such an response. Thus, we compared RFS at 3
years posttransplantation in the 2 groups, and found that
detection of MiHA-speciﬁc T cell responses was associated
with improved RFS in both the complete cohort (RFS of 69%
versus 51%; P¼ .03, univariate analysis) (Figure 5C), as well as
in the sibling graft recipients (RFS of 73% versus 52%; P ¼ .01,
univariate analysis) (Figure 5D). Notably, this association
with improved RFS at 3 years after allo-SCT can be attributedort
te Analysis
ing Risk Factors HR (95% CI) P Value
e, diagnosis, year of transplantation, stem
e, conditioning regimen
4.20 (1.60-10.90) .004
NA NA
NA NA
NA NA
, year of transplantation, stem cell source,
ing regimen
0.65 (0.40-1.08) .095
, year of transplantation, stem cell source,
ing regimen
0.77 (0.50-1.11) .14
e, diagnosis, year of transplantation,
source, conditioning regimen
0.81 (0.52-1.27) .35
e, diagnosis, year of transplantation,
source, conditioning regimen
0.68 (0.48-0.98) .04
NA NA
NA NA
NA NA
e, year of transplantation, cytomegalovirus
ve, aGVHD grade II-IV
0.59 (0.29-1.25) .19
-rank tests. Associations with the cumulative incidence of aGVHD, cGVHD,
he Gray test. Furthermore, in case a P valuewas0.20 in univariate analyses,
analyses (for the endpoints aGVHD, cGVHD, relapse, and NRM)were used to
Figure 4. Patients with MM undergoing allo-SCT with a related MiHA-mismatched graft show improved RFS. Recipients of sibling grafts were grouped based on
autosomal MiHA disparity in mismatching and matching at the DNA level. (A and B) Differences in RFS (A) and relapse rate (B) between these subgroups were
analyzed using the log-rank test and Fine-Gray competing-risk regression model, respectively. P values of univariate analyses are given. (C and D) The incidence of
cGVHD (C) and disease status (D) were analyzed using the Fisher exact test. (E) Within the total of mismatched MiHA, the relative contribution of each MiHA is
depicted. Lim indicates limited; Ext, extensive; Int, intermediate disease; Adv, advanced disease; ns, not signiﬁcant.
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response (complete cohort: relapse rate of 26% versus 39%,
P ¼ .09; sibling graft recipients: relapse rate of 24% versus
40%, P ¼ .047), and to a lesser extent to improved NRM
(complete cohort: NRM of 5% versus 10%, P ¼ .26; sibling
graft recipients: NRM of 3% versus 9%, P ¼ .10), as assessed in
univariate Fine-Gray competing-risk analyses. Despite the
inclusion of T cell responses against ubiquitously expressed
MiHAs, including HA8 and HY (ie, 17 of 40 in the complete
cohort and 17 of 35 in the sibling graft recipients), the rates of
grade III-IV aGVHD (P > .70) and limited/extensive cGVHD
were not affected (P > .20; both univariate Fine-Gray
competing-risk analysis). To conclude, these results indi-
cate that productive MiHA-speciﬁc T cell responses
contribute to the beneﬁcial GVT immunity after partially T
celledepleted allo-SCT.
DISCUSSION
As the dominant target antigens in HLA-matched allo-
SCT, MiHAs play pivotal roles in both GVT responses and
GVHD. A precise understanding of involved MiHA-speciﬁc T
cell responses not only may lead to better prediction of
clinical outcome in allo-SCT recipients, but also may provide
a rationale for selection of the most potent MiHAs in post-
transplantation immunotherapy. Interestingly, our statistical
analysis of immunogenic MiHA disparity rates in sibling graft
recipients revealed that DNA mismatches in autosomal-
encoded MiHAs are associated with improved clinical
outcome. In particular, patients with MM had a lower rate of
relapse and increased RFS when undergoing allo-SCT with an
MiHA-mismatched sibling transplant. In addition, we found
considerable variance in the relative immunogenicity of
different MiHAs in inducing productive T cell responsesposttransplantation. Most important, the presence of these
MiHA-speciﬁc Tcell responses was associatedwith improved
GVT immunity after partially T celledepleted allo-SCT.
Characteristics of all recipients and their corresponding
donors were analyzed for clinical outcome parameters
(Table 3). Importantly, we observed that mismatched auto-
somal MiHA, including those with a ubiquitous expression
pattern, were not correlated with higher incidence rates of
severe acute or chronic GVHD after partially T cell-depleted
SCT. In accordance with previous reports, only the HY
MiHAwas associated with increased frequency of grade III-IV
aGVHD. Similar ﬁndings have been reported by Gratwohl
et al. [18] and Stern et al. [31], who used female-to-male
alloreactivity as a model for HY MiHA mismatches.
However, along with MiHAs, noninheritedmaternal antigens
(NIMAs) and noninherited paternal antigens (NIPAs) are also
involved in female donor to male recipient transplants. Re-
ported rates of aGVHD are lower in noneT celledepleted
haploidentical sibling NIMA-mismatched allo-SCT than in
NIPA-mismatched allo-SCT [32]. In the present study, we
have no information on the NIMA or NIPA status of the
transplant couples and cannot exclude a possible inﬂuence of
these antigens on clinical outcome after partially T
celledepleted allo-SCT. Moreover, unknown MiHAs not
included in our panel might be important, as may other
general genetic disparities. Thus, we analyzed sibling graft
recipients separately, thereby circumventing the greater
likelihood of unknown polymorphic differences between
recipients and donors. Analysis again revealed a role of HY
MiHA disparity, and although more cases of severe aGVHD
(grade III-IV) were observed, this sex mismatch showed
a trend toward a lower incidence of relapse (P ¼ .095)
(Table 3), as had been reported by Gratwohl et al. [18].
Figure 5. Detection of tetramer-positive MiHA-speciﬁc CD8þ T cell responses is associated with improved RFS after allo-SCT. Recipient PBMC samples obtained after
allo-SCT were analyzed for the presence of MiHA-speciﬁc CD8þ T cells using a dual-color MiHA-multimer ﬂow cytometry assay. Patients were considered to have
a positive tetramer response when MiHA-speciﬁc CD8þ T cells were found directly after thawing or at 7 days after stimulation with peptide-loaded EBV-LCL. (A) The
numbers in the dot plots indicate the percentage of MiHA-speciﬁc cells positive for both tetramers (PE and APC) in the CD8þ, CD4, CD14, CD16, and CD19 T cell
populations. Three representative examples are shown. (B) For each MiHA disparity, the number of tetramer-positive responses (white bars) within the total number
of screenings (gray bars) is depicted for the complete cohort of MiHA-mismatched recipients. Percentages indicate the relative number of productive responses.
(C and D) RFS was analyzed for the complete cohort of recipients (C) versus recipients of a sibling graft (D) using the log-rank test. Groups were categorized based on
detection of MiHA-speciﬁc T cell responses (black line) versus no MiHA-speciﬁc T cell responses or no mismatching for any of the studied MiHAs (gray line) after allo-
SCT. Statistical differences in RFS incidence were analyzed using Kaplan-Meier point estimates and their associated errors; univariate P values are given.
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known autosomal MiHA was associated with higher RFS,
with no associated increase in aGVHD incidence or severity
after partially T celledepleted allo-SCT. This contribution of
autosomal MiHA mismatches to improved RFS in the sibling
transplant setting is even more apparent when compared
with recipients of an MUD graft. No effects of mismatched
MiHA on RFS were seen in the MUD graft recipients, which
might be attributed to the smaller size of this cohort.
Furthermore, these MUD recipients received ATG treatment
[20], which results in an additional in vivo T cell depletion,
thereby reducing the likelihood of inducing tumor-reactive
MiHA-speciﬁc T cell responses.
Along with the role of alloreactive T cells in the GVT
response, the underlying malignancy of the recipients might
be important as well. We found that autosomal MiHA
disparity in sibling transplants was associatedwith improved
RFS in multivariate analysis, which included correction for
diagnosis subgroups, suggesting a diagnosis-independent
effect; however, we could conﬁrm a signiﬁcant correlation
betweendisparate autosomalMiHAand improvedRFS only in
the MM subgroup. The lack of similar effects in the other
diagnosis subgroups could be related to differences in
immune susceptibility of the various tumors and the number
of patients included in this study. Furthermore, partially T
celledepleted SCT results in low rates of aGVHD and cGVHD,
which might have downgraded the clinical impact of MiHA
mismatches. When focusing on patients with MM in the
sibling graft recipients, we noted an evident association
between MiHA disparity and both relapse incidence and RFS
independent of disease status. Moreover, MiHA disparity was
also associated with a higher incidence of limited cGVHD.
These ﬁndings indicate that patients with MM can derive
particular beneﬁt from an MiHA-driven GVT effect in the
presence of an acceptable degree of cGVHD. MM is an
immunogenic tumor, and affected patients can respond well
to DLI [33,34]. This phenomenon could be linked to multiple
factors, likely including high antigen presentation, good
susceptibility to killing, and possibly a good window for
immune recognition and killing owing to the relatively slow
tumor growth. Furthermore, posttransplantation treatment
with immunomodulatory drugs, such as lenalidomide, has
a promoting effect on GVT immunity.
Overall, we found a low incidence of aGVHD (6.5% grade
III-IV) in our partially T celledepleted setting, even when
ubiquitously expressed MiHAmismatches were present. This
indicates a potential safe clinical application for transplant
mismatching of certain strongly immunogenicMiHAs in allo-
SCT. In previous studies, theMiHAsHA1, HA2, LRH1, andACC1
have been implicated in selective induction of a GVT effect
without GVHD [7,35-37]. We have shown that these MiHAs
are also potent in inducing MiHA-speciﬁc T cell responses
in vivo, adding to the promise of these MiHA not only in
transplant mismatching, but also in vaccination and adoptive
T cell strategies. However, timing of the tetramer-based
analysis of posttransplantation PBMC samples is crucial in
detecting MiHA-speciﬁc T cell responses, and our study had
a rather wide time frame of sampling after allo-SCT, which
likely resulted in underscoring the frequency of positive
responses. In addition, some of the MiHA-speciﬁc T cell
responses could be masked (subdominant) by other (un)
known MiHAs. Moreover, the underlying malignancy might
skew the MiHA-speciﬁc T cell repertoire toward a particular
hematopoietic compartment such as the BM, which may
prevent the detection of MiHA-speciﬁc T cells in peripheralblood. Thus, the absence of tetramer-positive T cells in our
analyses does not necessarily mean a complete lack of MiHA-
speciﬁc T cells in vivo. Nevertheless, we found that the
presence of MiHA-speciﬁc T cell responses resulted in
improved RFS at 3 years after allo-SCT despite the heteroge-
neity of our cohort. After 5 years, the RFS curves of patients
with and without MiHA-speciﬁc immunity no longer
differed, however. Because the group size was relatively
limited at the start of the study and decreased even further
over time owing to positive events or censoring of patients,
our data are likely less reliable at later time points. Further-
more, due to the heterogeneity of the cohort, over time the
patient group is likely skewed toward late-relapsing malig-
nancies with low immunogenicity. It also could be that the
patients who develop late relapse have impaired MiHA-
speciﬁc T cell immunity due to immune escape mechanisms
exploited by surviving tumor cells, such as the PD-1/PD-L1
and BTLA/HVEM coinhibitory pathways, as we reported
previously [38,39]. Owing to this negative signaling, T cells
can become exhausted over time, and patients may lose the
advantage of MiHA-speciﬁc immunity posttransplantation.
Importantly, the occurrence of in vivoMiHA-speciﬁc T cell
responses, including those recognizing ubiquitously expres-
sed MiHAs, amongst which the HY antigens, was not associ-
ated with an increased incidence of severe aGVHD or cGVHD.
Unfortunately, the group of patientswithMiHA-speciﬁc Tcell
immunity was too small to allow us to focus on diagnosis
subgroups or perform multivariate analyses. Thus, our ﬁnd-
ings need to be conﬁrmed in a larger and more homogenous
cohort of allo-SCT recipients with longer follow-up.
In conclusion, this study shows that MiHA mismatch is
associated with improved clinical outcome after partially T
celledepleted HLA-matched allo-SCT, particularly in patients
with MM and likely in patients with other hematologic
malignancies as well. The observed positive effects might be
attributed to the induction of GVT responses by MiHA-
speciﬁc CD8þ T cells. Not all MiHAs seem to have the same
potential to induce MiHA-speciﬁc T cells, however, as
demonstrated by our tetramer analysis of PBMC samples
collected posttransplantation. Further study of the MiHAs
that are most productive in this respect will allow selection
of hematopoietic-restricted MiHAs as safe and potent target
antigens in allo-SCT to prevent or treat tumor recurrence
with posttransplantation immunotherapeutic strategies.
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